Latest On CymaBay Therapeutics, Inc (CBAY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-16 11:35 EST | News | CymaBay Therapeutics, Inc. (CBAY) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-15 22:01 EST | News | CymaBay Therapeutics GAAP EPS of -$0.29 misses by $0.19 | N/A | |
| 2023-05-14 18:32 EST | News | CymaBay Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-05-10 01:05 EST | News | CymaBay Therapeutics: Slow But Steady Progress | N/A | |
| 2023-05-09 10:43 EST | News | CymaBay names new finance chief | N/A | |
| 2023-04-05 20:14 EST | News | CymaBay initiated at outperform at William Blair on liver disease candidate | N/A | |
| 2023-03-17 06:48 EST | News | CymaBay Therapeutics GAAP EPS of -$0.30 misses by $0.01 | N/A | |
| 2023-03-17 06:48 EST | News | CymaBay Therapeutics, Inc. (CBAY) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-16 00:39 EST | News | CymaBay Therapeutics Q4 2022 Earnings Preview | N/A | |
| 2023-02-23 12:56 EST | News | CymaBay: Long Term Is Constructive With Potential Seladelpar Conversion | N/A | |
| 2023-01-24 13:33 EST | News | CymaBay gains on pricing of $85.05M public offering | N/A | |
| 2023-01-24 01:22 EST | News | CymaBay stock pops 7% after launching stock and warrants offering | N/A | |
| 2023-01-09 14:25 EST | News | CymaBay join hands with Kaken to develop, commercialize Seladelpar | N/A | |
| 2022-11-15 16:42 EST | News | CymaBay Therapeutics, Inc. (CBAY) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-14 23:54 EST | News | CymaBay Therapeutics GAAP EPS of -$0.28 beats by $0.02 | N/A | |
| 2022-11-14 06:41 EST | News | CymaBay Therapeutics Q3 2022 Earnings Preview | N/A | |
| 2022-08-12 00:16 EST | News | CymaBay Therapeutics (CBAY) Investor Presentation - Slideshow | N/A | |
| 2022-08-12 00:16 EST | News | CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01 | N/A | |
| 2022-08-12 00:16 EST | News | Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-11 07:21 EST | News | CymaBay Therapeutics Q2 2022 Earnings Preview | N/A | |
| 2022-06-28 01:15 EST | News | CymaBay: Long-Term Potential Based On Prior PBC Trial Results | N/A | |
| 2022-06-08 01:36 EST | News | CymaBay Therapeutics stock gains after CEO buys shares worth $100K | N/A | |
| 2022-05-23 15:48 EST | News | CymaBay announces result from two-year study of primary biliary cholangitis therapy | N/A | |
| 2022-05-17 04:34 EST | News | CymaBay price target lowered at H.C. Wainwright on enrollment delay for key study | N/A | |
| 2022-05-13 08:30 EST | News | CymaBay Therapeutics GAAP EPS of -$0.32 misses by $0.01 | N/A | |
| 2022-05-13 08:30 EST | News | CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-11 20:50 EST | News | CymaBay Therapeutics Q1 2022 Earnings Preview | N/A | |
| 2022-04-05 06:49 EST | News | CymaBay announces result from Phase 2 trial of primary biliary cholangitis therapy | N/A | |
| 2022-03-18 14:40 EST | News | CymaBay Therapeutics GAAP EPS of -$0.34 misses by $0.11 | N/A | |
| 2022-03-18 14:40 EST | News | CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-17 04:17 EST | News | CymaBay Therapeutics Q4 2021 Earnings Preview | N/A | |
| 2022-01-22 00:44 EST | News | CymaBay on the rise after insider purchase of chief medical officer | N/A | |
| 2022-01-20 17:14 EST | News | Why I've Taken A 'Starter' Position In CymaBay Therapeutics | N/A | |
| 2021-11-18 11:55 EST | News | CymaBay Therapeutics announces public offering of common stock and warrants | N/A | |
| 2021-11-18 11:55 EST | News | CymaBay Therapeutics prices ~$75M offering | N/A | |
| 2021-11-15 22:19 EST | News | CymaBay Therapeutics shares long-term bio marker data for liver disease therapy | N/A | |
| 2021-11-11 03:06 EST | News | CymaBay Therapeutics EPS misses by $0.08 | N/A | |
| 2021-11-10 04:31 EST | News | CymaBay Therapeutics Q3 2021 Earnings Preview | N/A | |
| 2021-08-13 10:37 EST | News | CymaBay Therapeutics EPS misses by $0.07 | N/A | |
| 2021-08-13 10:37 EST | News | CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-02 14:09 EST | News | CymaBay receives $100M non-dilutive financing for late-stage trial of liver disease drug | N/A | |
| 2021-03-26 06:19 EST | News | CymaBay Therapeutics EPS misses by $0.03 | N/A | |
| 2021-03-26 06:19 EST | News | Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-18 12:19 EST | Analyst Rating | The Analyst Target Price has increased from $13.09 to $13.4. | Buy | |
| 2021-02-17 18:37 EST | News | CymaBay Therapeutics: Checking In On This Roller Coaster Stock | N/A | |
| 2020-12-13 03:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-01 11:27 EST | Analyst Rating | The Analyst Target Price has increased from $13 to $13.09. | Buy | |
| 2020-11-18 09:40 EST | News | CymaBay Therapeutics (CBAY) Presents At AASLD 2020 Conference- Slideshow | N/A | |
| 2020-11-15 11:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-14 23:16 EST | News | Stocks To Watch: Spotlight On Nvidia, Walmart, JD.com And Nio | N/A | |
About CymaBay Therapeutics, Inc (CBAY):
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
General
- Name CymaBay Therapeutics, Inc
- Symbol CBAY
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 36
- Fiscal Year EndDecember
- IPO Date2014-02-03
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.cymabay.com
View More
Valuation
- Price/Book (Most Recent Quarter) 2.2
- Enterprise Value EBITDA 0.64
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.20
- Return on Assets -20%
- Return on Equity -35%
- Earnings Per Share -$1.38
- Revenue Per Share $0
- Gross Profit -64579000
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 328.59 million
- EBITDA -91225000
- Analyst Target Price $13.4
- Book Value Per Share $2.27
View More
Share Statistics
- Shares Outstanding 68.89 million
- Shares Float 50.35 million
- % Held by Insiders 40%
- % Held by Institutions 84.85%
- Shares Short 8.34 million
- Shares Short Prior Month 6.82 million
- Short Ratio 5.45
- Short % of Float 12%
- Short % of Shares Outstanding 12%
View More
Technicals
- Beta 1.25
- 52 Week High $9.06
- 52 Week Low $1.33
- 50 Day Moving Average 5.31
- 200 Day Moving Average 6.62
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
CymaBay Therapeutics, Inc (CBAY) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
CymaBay Therapeutics, Inc (CBAY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-05 | $N/A | -$0.17 | -$0.17 | 0% |
| 2020-06-30 | 2020-08-10 | $N/A | -$0.16 | -$0.24 | 31.91% |
| 2020-03-31 | 2020-05-11 | $N/A | -$0.19 | -$0.31 | 39% |
| 2019-12-31 | 2020-03-12 | $N/A | -$0.35 | -$0.38 | 6.87% |
| 2019-09-30 | 2019-11-05 | $N/A | -$0.38 | -$0.36 | -4.28% |
| 2019-06-30 | 2019-08-07 | $N/A | -$0.35 | -$0.37 | 5.2% |
| 2019-03-31 | 2019-05-08 | $N/A | -$0.37 | -$0.34 | -8.82% |
| 2018-12-31 | 2019-02-28 | $N/A | -$0.32 | -$0.35 | 9.32% |
| 2018-09-30 | 2018-11-06 | $N/A | -$0.31 | -$0.29 | -6.9% |
| 2018-06-30 | 2018-08-09 | $N/A | -$0.30 | -$0.25 | -21.95% |
| 2018-03-31 | 2018-05-08 | $N/A | -$0.32 | -$0.13 | -146.15% |
| 2017-12-31 | 2018-03-15 | $5.21 million | -$0.11 | -$0.23 | 51.48% |
| 2017-09-30 | 2017-11-08 | $N/A | -$0.21 | -$0.18 | -15.07% |
| 2017-06-30 | 2017-08-10 | $-4793000 | -$0.31 | -$0.26 | -21.57% |
| 2017-03-31 | 2017-05-11 | $4.79 million | -$0.20 | -$0.26 | 23.08% |
| 2016-12-31 | 2017-03-23 | $N/A | -$0.30 | -$0.28 | -5.89% |
| 2016-09-30 | 2016-11-09 | $N/A | -$0.25 | -$0.31 | 19.35% |
| 2016-06-30 | 2016-08-09 | $N/A | -$0.30 | -$0.32 | 5.27% |
| 2016-03-31 | 2016-05-11 | $N/A | -$0.29 | -$0.28 | -3.57% |
| 2015-12-31 | 2016-03-29 | $N/A | -$0.26 | -$0.35 | 25.71% |
| 2015-09-30 | 2015-11-12 | $N/A | -$0.27 | -$0.33 | 18.18% |
| 2015-06-30 | 2015-08-10 | $N/A | -$0.09 | -$0.42 | 78.57% |
| 2015-03-31 | 2015-05-07 | $N/A | -$0.15 | -$0.44 | 65.91% |
| 2014-12-31 | 2015-03-18 | $N/A | -$0.87 | -$0.47 | -85.11% |
| 2014-09-30 | 2014-11-12 | $N/A | -$0.44 | -$0.47 | 6.38% |
| 2014-06-30 | 2014-08-14 | $N/A | -$0.56 | -$0.94 | 40.43% |
| 2014-03-31 | 2014-05-28 | $N/A | -$1.02 | ||
| 2013-12-31 | 2014-02-26 | $N/A | -$1.38 |
CymaBay Therapeutics, Inc (CBAY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 9.51 million | N/A | 23.19 million |
| Income Before Tax | N/A | N/A | -13.09 million | -29.41 million | -26.28 million |
| Selling General Administrative | 4.49 million | N/A | 4.35 million | 4.53 million | 4.51 million |
| Gross Profit | N/A | N/A | N/A | -20.94 million | N/A |
| Ebit | N/A | N/A | -13.7 million | -25.47 million | -27.71 million |
| Operating Income | N/A | N/A | -13.86 million | -25.47 million | -27.71 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | 20.94 million | N/A |
| Total Other Income Expense Net | 587000 | N/A | -71000 | -3.94 million | 1.43 million |
| Net Income From Continuing Operations | N/A | N/A | -13.09 million | -29.41 million | -26.28 million |
| Net Income Applicable to Common Shares | N/A | -10.73 million | -13.09 million | -29.41 million | -26.28 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -41.31 million | N/A | N/A | N/A | 38.53 million |
| Change to Liabilities | 1.07 million | -737000 | N/A | N/A | -1.39 million |
| Total Cash Flow from Investing Activities | -41.33 million | 47 million | 46.63 million | N/A | 38.51 million |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Operating Activities | N/A | 2.7 million | N/A | N/A | 2.12 million |
| Change in Cash | -48.78 million | N/A | 31.93 million | N/A | 15.38 million |
| Total Cash from Operating Activities | -7.45 million | -7.75 million | -14.71 million | N/A | -23.13 million |
| Depreciation | 225000 | N/A | 153000 | N/A | 144000 |
| Other Cash Flow from Investing Activities | N/A | N/A | 46.63 million | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 2.55 million | 862000 | N/A | N/A | 2.28 million |
| Capital Expenditures | 21000 | N/A | N/A | N/A | 20000 |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | 13.55 million | N/A | 19.21 million |
| Total Stockholder Equity | N/A | N/A | 175.05 million | 212.59 million | 212.59 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | N/A | N/A | 188.6 million | N/A | 231.8 million |
| Common Stock | N/A | 7000 | 7000 | N/A | 7000 |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | -649.69 million | -638.96 million | N/A | -596.46 million |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | 160000 | 160000 | N/A | 1.26 million |
| Cash | N/A | N/A | 56.79 million | N/A | 43.46 million |
| Total Current Liabilities | 10.46 million | N/A | 11.92 million | N/A | 17.36 million |
| Other Stockholder Equity | N/A | 186000 | -130000 | N/A | 177000 |
| Property, Plant & Equipment | N/A | 2.34 million | 2.49 million | N/A | 2.77 million |
| Total Current Assets | N/A | N/A | 185.95 million | N/A | 227.77 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | N/A | 165.61 million | N/A | 212.59 million | 212.59 million |
| Short Term Investments | N/A | N/A | 119.44 million | N/A | 175.13 million |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 947000 | N/A | 1.21 million | N/A | 1.49 million |
CymaBay Therapeutics, Inc (CBAY) Chart:
CymaBay Therapeutics, Inc (CBAY) News:
Below you will find a list of latest news for CymaBay Therapeutics, Inc (CBAY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
CymaBay Therapeutics, Inc (CBAY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-16 | 2 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2026-01-16 | 3 | 0 | CALL | 0 | 0 | 279.17 | TRUE | 0 | 0 |
| 2026-01-16 | 4 | 0 | CALL | 0 | 0 | 205.68 | TRUE | 0 | 0 |
| 2026-01-16 | 5 | 17 | CALL | 1 | 6 | 170.44 | TRUE | 0 | 0 |
| 2026-01-16 | 8 | 9.2 | CALL | 1 | 2 | 116.04 | TRUE | 0 | 0 |
| 2026-01-16 | 10 | 7.5 | CALL | 1 | 1 | 94.87 | TRUE | 0 | 0 |
| 2026-01-16 | 13 | 0 | CALL | 0 | 0 | 72.05 | TRUE | 0 | 0 |
| 2026-01-16 | 15 | 17.3 | CALL | 111 | 79 | 60.26 | TRUE | 0 | 0 |
| 2026-01-16 | 17 | 16.6 | CALL | 40 | 41 | 48.59 | TRUE | 0 | 0 |
| 2026-01-16 | 20 | 12 | CALL | 0 | 7 | 37.42 | TRUE | 0 | 0 |
| 2026-01-16 | 22 | 9.5 | CALL | 1 | 2 | 29.97 | TRUE | 0 | 0 |
| 2026-01-16 | 25 | 7.5 | CALL | 0 | 5 | 19.9 | TRUE | 0 | 0 |
| 2026-01-16 | 27 | 5.5 | CALL | 0 | 20 | 13.46 | TRUE | 0 | 0 |
| 2026-01-16 | 30 | 2.53 | CALL | 0 | 81 | 0 | TRUE | 0 | 0 |
| 2026-01-16 | 32 | 0.55 | CALL | 0 | 106 | 0 | TRUE | 0 | 0 |
| 2026-01-16 | 35 | 0.05 | CALL | 0 | 1128 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 37 | 0.05 | CALL | 0 | 56 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 40 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 42 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 45 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 2 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 3 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 4 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 8 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 10 | 0.05 | PUT | 0 | 265 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 13 | 0.05 | PUT | 0 | 221 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 15 | 0.45 | PUT | 0 | 10 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 17 | 0.11 | PUT | 1 | 10 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 20 | 0.05 | PUT | 0 | 66 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 22 | 0.05 | PUT | 0 | 10 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 25 | 0.5 | PUT | 0 | 20 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 27 | 0.25 | PUT | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 30 | 0.05 | PUT | 0 | 1984 | 6.77 | FALSE | 0 | 0 |
| 2026-01-16 | 32 | 0.05 | PUT | 0 | 346 | 3.68 | FALSE | 0 | 0 |
| 2026-01-16 | 35 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2026-01-16 | 37 | 0 | PUT | 0 | 0 | 26.13 | TRUE | 0 | 0 |
| 2026-01-16 | 40 | 0 | PUT | 0 | 0 | 31.95 | TRUE | 0 | 0 |
| 2026-01-16 | 42 | 0 | PUT | 0 | 0 | 41.69 | TRUE | 0 | 0 |
| 2026-01-16 | 45 | 0 | PUT | 0 | 0 | 46.37 | TRUE | 0 | 0 |
Latest CBAY Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 100 | $2.13 |
| Jun 13, 2022 7:59 PM EST | 100 | $2.13 |
| Jun 13, 2022 7:59 PM EST | 100 | $2.13 |
| Jun 13, 2022 7:59 PM EST | 100 | $2.125 |
| Jun 13, 2022 7:59 PM EST | 95 | $2.125 |
CymaBay Therapeutics, Inc (CBAY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1042074/000119312520186924/0001193125-20-186924-index.htm |
| 2019-02-08 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1042074/000000000019001619/0000000000-19-001619-index.htm |
| 2020-04-29 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1042074/000000000020003682/0000000000-20-003682-index.htm |
| 2020-04-30 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1042074/000000000020003706/0000000000-20-003706-index.htm |
| 2020-07-08 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1042074/000000000020006119/0000000000-20-006119-index.htm |
| 2019-02-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000021545719006853/0000215457-19-006853-index.htm |
| 2018-02-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000031506618000964/0000315066-18-000964-index.htm |
| 2018-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000031506618000982/0000315066-18-000982-index.htm |
| 2018-06-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000031506618001965/0000315066-18-001965-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000031506619000977/0000315066-19-000977-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000083423720005413/0000834237-20-005413-index.htm |
| 2019-06-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000089914019000419/0000899140-19-000419-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000089914020000177/0000899140-20-000177-index.htm |
| 2018-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000090266418000963/0000902664-18-000963-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000090266419000934/0000902664-19-000934-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000090266420001122/0000902664-20-001122-index.htm |
| 2020-08-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000090266420002879/0000902664-20-002879-index.htm |
| 2020-09-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000090266420003215/0000902664-20-003215-index.htm |
| 2018-02-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000117/0000905718-18-000117-index.htm |
| 2018-02-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000123/0000905718-18-000123-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000191/0000905718-18-000191-index.htm |
| 2018-02-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000256/0000905718-18-000256-index.htm |
| 2018-02-16 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000260/0000905718-18-000260-index.htm |
| 2018-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000263/0000905718-18-000263-index.htm |
| 2018-03-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000307/0000905718-18-000307-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000559/0000905718-18-000559-index.htm |
| 2018-06-11 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000561/0000905718-18-000561-index.htm |
| 2018-12-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000979/0000905718-18-000979-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000090571819000089/0000905718-19-000089-index.htm |
| 2019-12-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000090571819000983/0000905718-19-000983-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000090571820000204/0000905718-20-000204-index.htm |
| 2019-12-12 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1042074/000092189519002974/0000921895-19-002974-index.htm |
| 2020-02-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1042074/000092189520000502/0000921895-20-000502-index.htm |
| 2020-03-13 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1042074/000092189520000746/0000921895-20-000746-index.htm |
| 2020-04-24 | PREC14A | Preliminary proxy statements, contested solicitations | https://www.sec.gov/Archives/edgar/data/1042074/000092189520001187/0000921895-20-001187-index.htm |
| 2020-05-01 | PRRN14A | Non-management revised preliminary proxy soliciting materials, contested and otherwise | https://www.sec.gov/Archives/edgar/data/1042074/000092189520001253/0000921895-20-001253-index.htm |
| 2019-12-20 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000110465919074965/0001104659-19-074965-index.htm |
| 2020-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000110465920016437/0001104659-20-016437-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000110465920020461/0001104659-20-020461-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000110465920021706/0001104659-20-021706-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000110465920021752/0001104659-20-021752-index.htm |
| 2020-06-05 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000110465920070289/0001104659-20-070289-index.htm |
| 2018-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000114420418007655/0001144204-18-007655-index.htm |
| 2018-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000114420418007939/0001144204-18-007939-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000114420419007019/0001144204-19-007019-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000114420419007219/0001144204-19-007219-index.htm |
| 2018-03-15 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1042074/000119312518084086/0001193125-18-084086-index.htm |
| 2018-04-20 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1042074/000119312518124922/0001193125-18-124922-index.htm |
| 2018-04-20 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1042074/000119312518124946/0001193125-18-124946-index.htm |
| 2018-04-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312518124952/0001193125-18-124952-index.htm |
| 2018-06-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312518186789/0001193125-18-186789-index.htm |
| 2018-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312518203198/0001193125-18-203198-index.htm |
| 2018-08-09 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1042074/000119312518244510/0001193125-18-244510-index.htm |
| 2018-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312518311306/0001193125-18-311306-index.htm |
| 2018-12-28 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1042074/000119312518360899/0001193125-18-360899-index.htm |
| 2019-02-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312519027117/0001193125-19-027117-index.htm |
| 2019-02-07 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1042074/000119312519030856/0001193125-19-030856-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000119312519040900/0001193125-19-040900-index.htm |
| 2019-02-28 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1042074/000119312519057404/0001193125-19-057404-index.htm |
| 2019-03-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1042074/000119312519064180/0001193125-19-064180-index.htm |
| 2019-03-06 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1042074/000119312519065621/0001193125-19-065621-index.htm |
| 2019-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312519065635/0001193125-19-065635-index.htm |
| 2019-03-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000119312519070099/0001193125-19-070099-index.htm |
| 2019-04-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1042074/000119312519122315/0001193125-19-122315-index.htm |
| 2019-04-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1042074/000119312519122346/0001193125-19-122346-index.htm |
| 2019-06-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312519173660/0001193125-19-173660-index.htm |
| 2019-09-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312519246916/0001193125-19-246916-index.htm |
| 2019-12-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312519319305/0001193125-19-319305-index.htm |
| 2020-01-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312520018430/0001193125-20-018430-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000119312520038342/0001193125-20-038342-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312520071549/0001193125-20-071549-index.htm |
| 2020-03-13 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1042074/000119312520073117/0001193125-20-073117-index.htm |
| 2020-03-16 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1042074/000119312520074946/0001193125-20-074946-index.htm |
| 2020-04-21 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1042074/000119312520113689/0001193125-20-113689-index.htm |
| 2020-04-27 | PREC14A | Preliminary proxy statements, contested solicitations | https://www.sec.gov/Archives/edgar/data/1042074/000119312520121016/0001193125-20-121016-index.htm |
| 2020-04-29 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1042074/000119312520123459/0001193125-20-123459-index.htm |
| 2020-05-05 | PRER14A | Preliminary Proxy Soliciting materials | https://www.sec.gov/Archives/edgar/data/1042074/000119312520133758/0001193125-20-133758-index.htm |
| 2020-05-05 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1042074/000119312520133766/0001193125-20-133766-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312520139014/0001193125-20-139014-index.htm |
| 2020-05-11 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1042074/000119312520139023/0001193125-20-139023-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1042074/000119312520139038/0001193125-20-139038-index.htm |
| 2020-05-11 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1042074/000119312520139262/0001193125-20-139262-index.htm |
| 2020-05-15 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1042074/000119312520143963/0001193125-20-143963-index.htm |
| 2020-06-05 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1042074/000119312520162306/0001193125-20-162306-index.htm |
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1042074/000119312520180903/0001193125-20-180903-index.htm |
| 2020-07-02 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1042074/000119312520186924/0001193125-20-186924-index.htm |
| 2020-07-09 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1042074/000119312520190437/0001193125-20-190437-index.htm |
| 2020-07-14 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1042074/000119312520192616/0001193125-20-192616-index.htm |
| 2020-07-14 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1042074/000119312520192617/0001193125-20-192617-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1042074/000119312520214900/0001193125-20-214900-index.htm |
| 2020-09-24 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000119312520253460/0001193125-20-253460-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1042074/000119312520286811/0001193125-20-286811-index.htm |
| 2020-05-13 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1042074/000119380520000573/0001193805-20-000573-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000120919120030579/0001209191-20-030579-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000120919120030583/0001209191-20-030583-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000120919120030585/0001209191-20-030585-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000120919120030587/0001209191-20-030587-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000120919120030592/0001209191-20-030592-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000120919120030595/0001209191-20-030595-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000120919120030600/0001209191-20-030600-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000120919120030603/0001209191-20-030603-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000120919120038529/0001209191-20-038529-index.htm |
| 2019-08-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000131924419000068/0001319244-19-000068-index.htm |
| 2020-01-23 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1042074/000131924420000016/0001319244-20-000016-index.htm |
| 2018-03-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000035/0001333277-18-000035-index.htm |
| 2018-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000036/0001333277-18-000036-index.htm |
| 2018-07-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000037/0001333277-18-000037-index.htm |
| 2018-08-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000039/0001333277-18-000039-index.htm |
| 2018-10-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000040/0001333277-18-000040-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000041/0001333277-18-000041-index.htm |
| 2019-01-31 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000018/0001333277-19-000018-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000019/0001333277-19-000019-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000020/0001333277-19-000020-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000021/0001333277-19-000021-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000022/0001333277-19-000022-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000023/0001333277-19-000023-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000024/0001333277-19-000024-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000025/0001333277-19-000025-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000026/0001333277-19-000026-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000027/0001333277-19-000027-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000028/0001333277-19-000028-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000029/0001333277-19-000029-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000030/0001333277-19-000030-index.htm |
| 2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000031/0001333277-19-000031-index.htm |
| 2019-02-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000034/0001333277-19-000034-index.htm |
| 2019-08-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000041/0001333277-19-000041-index.htm |
| 2019-08-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000042/0001333277-19-000042-index.htm |
| 2019-09-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000044/0001333277-19-000044-index.htm |
| 2019-10-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000046/0001333277-19-000046-index.htm |
| 2020-10-13 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327720000003/0001333277-20-000003-index.htm |
| 2020-10-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1042074/000133327720000005/0001333277-20-000005-index.htm |
| 2018-03-15 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1042074/000156459018005831/0001564590-18-005831-index.htm |
| 2018-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1042074/000156459018011853/0001564590-18-011853-index.htm |
| 2018-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1042074/000156459018021029/0001564590-18-021029-index.htm |
| 2018-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1042074/000156459018027388/0001564590-18-027388-index.htm |
| 2019-02-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1042074/000156459019005435/0001564590-19-005435-index.htm |
| 2019-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1042074/000156459019017174/0001564590-19-017174-index.htm |
| 2019-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1042074/000156459019030039/0001564590-19-030039-index.htm |
| 2019-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1042074/000156459019040357/0001564590-19-040357-index.htm |
| 2019-02-11 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1042074/999999999519000163/9999999995-19-000163-index.htm |
| 2020-07-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1042074/999999999520001791/9999999995-20-001791-index.htm |
| 2020-08-28 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1042074/999999999720004532/9999999997-20-004532-index.htm |
CymaBay Therapeutics, Inc (CBAY) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of CymaBay Therapeutics, Inc (CBAY). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 40%Institutional Ownership: 8485%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-03-22 | CARL GOLDFISCHER | Director | Sell | 15,000.00 | 13.03 | 195,375.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000035/0001333277-18-000035-index.htm |
| 2019-02-07 | CARL GOLDFISCHER | Director | Sell | 11,675.00 | 9.02 | 105,328.35 | 0.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000034/0001333277-19-000034-index.htm |
| 2018-08-29 | Daniel Menold | Vice President, Finance | Sell | 5,000.00 | 13.00 | 65,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000039/0001333277-18-000039-index.htm |
| 2018-10-15 | Sujal Shah | Chief Executive Officer | Buy | 5,000.00 | 9.90 | 49,500.00 | 100,000.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000040/0001333277-18-000040-index.htm |
| 2018-12-21 | Sujal Shah | Chief Executive Officer | Buy | 10,000.00 | 6.54 | 65,399.00 | 110,000.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000041/0001333277-18-000041-index.htm |
| 2019-09-20 | Sujal Shah | Chief Executive Officer | Buy | 1,900.00 | 5.50 | 10,450.00 | 111,900.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000044/0001333277-19-000044-index.htm |
| 2019-09-23 | Sujal Shah | Chief Executive Officer | Buy | 3,100.00 | 5.55 | 17,205.00 | 115,000.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000044/0001333277-19-000044-index.htm |
| 2019-02-07 | CARL GOLDFISCHER | Director | Buy | 9,340.00 | 5.50 | 51,370.00 | 11,675.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000034/0001333277-19-000034-index.htm |
| 2019-10-10 | Sujal Shah | Chief Executive Officer | Buy | 5,000.00 | 4.30 | 21,500.00 | 120,000.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000046/0001333277-19-000046-index.htm |
| 2018-12-18 | KURT VON EMSTER | Director | Sell | 53,492.00 | 7.43 | 397,365.32 | 131,036.00 | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000979/0000905718-18-000979-index.htm |
| 2018-03-22 | CARL GOLDFISCHER | Director | Buy | 5,660.00 | 5.50 | 31,130.00 | 15,000.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000035/0001333277-18-000035-index.htm |
| 2017-07-19 | KURT VON EMSTER | Director | Buy | 153,846.00 | 6.50 | 999,999.00 | 1,753,846.00 | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000123/0000905718-18-000123-index.htm |
| 2018-06-05 | KURT VON EMSTER | Director | Sell | 920.00 | 12.51 | 11,509.20 | 18,316.00 | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000559/0000905718-18-000559-index.htm |
| 2018-12-17 | KURT VON EMSTER | Director | Sell | 88,889.00 | 8.17 | 726,223.13 | 184,528.00 | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000979/0000905718-18-000979-index.htm |
| 2019-02-07 | CARL GOLDFISCHER | Director | Buy | 2,335.00 | 5.00 | 11,675.00 | 2,335.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327719000034/0001333277-19-000034-index.htm |
| 2018-03-05 | KURT VON EMSTER | Director | Sell | 13,353.00 | 15.51 | 207,105.03 | 273,417.00 | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000307/0000905718-18-000307-index.htm |
| 2018-02-15 | KURT VON EMSTER | Director | Sell | 68,712.00 | 14.49 | 995,636.88 | 286,770.00 | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000263/0000905718-18-000263-index.htm |
| 2018-02-14 | KURT VON EMSTER | Director | Sell | 162,979.00 | 16.69 | 2,720,119.51 | 355,482.00 | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000256/0000905718-18-000256-index.htm |
| 2018-02-07 | KURT VON EMSTER | Director | Sell | 40,763.00 | 12.35 | 503,423.05 | 419,693.00 | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000117/0000905718-18-000117-index.htm |
| 2018-08-29 | Daniel Menold | Vice President, Finance | Buy | 5,000.00 | 5.00 | 25,000.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000039/0001333277-18-000039-index.htm |
| 2018-02-13 | KURT VON EMSTER | Director | Sell | 55,078.00 | 13.51 | 744,103.78 | 518,461.00 | https://www.sec.gov/Archives/edgar/data/1042074/000090571818000256/0000905718-18-000256-index.htm |
| 2018-05-11 | Sujal Shah | Chief Executive Officer | Buy | 5,000.00 | 10.65 | 53,250.00 | 90,000.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000036/0001333277-18-000036-index.htm |
| 2018-03-22 | CARL GOLDFISCHER | Director | Buy | 9,340.00 | 5.00 | 46,700.00 | 9,340.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000035/0001333277-18-000035-index.htm |
| 2018-07-27 | Sujal Shah | Chief Executive Officer | Buy | 5,000.00 | 10.90 | 54,500.00 | 95,000.00 | https://www.sec.gov/Archives/edgar/data/1042074/000133327718000037/0001333277-18-000037-index.htm |